# Puliyan Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/puliyan-medical

- Industry: Medical Devices & Equipment
- Headquarters: Nanjing, China
- Website: www.puliyan.com
- Total disclosed funding: $50M
- Latest round: Series C (Jul 31, 2025)
- Investors on record: 4

## About

Based in China, Puliyan Medical specializes in developing and producing innovative medical devices focused on high polymer materials and biological tissue engineering.Puliyan Medical, formed in 2018 and headquartered in Nanjing, China, is dedicated to the medical devices sector. The company has raised a total of USD 50mn through its Series C funding round co-led by new investors Zhejiang Future Assets Mangement Company.ltd and Mirae Asset Capital, with participation from returning investors Alwin Capital and Huatai Zijin Investment on July 31, 2025.Puliyan Medical Technology Co., Ltd. specializes in the development and production of innovative medical devices primarily focused on high polymer materials and biological tissue engineering. The company's core product offerings include absorbable medical devices such as facial fillers, collagen dressings, and gel dressings. These products cater to the medical aesthetics market, addressing clinical needs for skin rejuvenation, anti-aging treatments, and post-surgical recovery.Puliyan Medical generates revenue through direct sales of its medical devices to healthcare professionals and aesthetic service providers. Utilizing a B2B structure, products are supplied directly to clinics and hospitals, with partnerships to enhance market reach. Key products include the Puliyan T polylactic acid facial fillers and various collagen-based treatment solutions, strategically priced for their high-quality formulation and innovative design. In July 2025, Puliyan Medical secured USD 50mn in Series C funding, which will primarily support research and development investments, marketing efforts, channel development, and production expansion for subsequent injectable medical aesthetic products. The company aims to introduce new products to the market while expanding its reach into additional regions, particularly targeting Southeast Asia and other international markets.

## Funding rounds

- Series C, Jul 31, 2025, $50M — Huatai Zijin Investment, Alwin Capital, Zhejiang Future Assets Mangement Company.ltd, Mirae Asset Capital (China)

## Investors

- Huatai Zijin Investment (https://capitalatlas.ai/funds/huatai-zijin-investment) — Series C
- Alwin Capital — Series C
- Zhejiang Future Assets Mangement Company.ltd — Series C
- Mirae Asset Capital (China) (https://capitalatlas.ai/funds/mirae-asset-capital-china) — Series C